Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDOV-2
- Development stage
- Unknown
- Lead developer
- ViroMissile
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
IDOV-2 (formerly known as IDOV-Immune) is an intravenously deliverable oncolytic virus (OV) being developed by ViroMissile, Inc. for the treatment of advanced solid tumors. It belongs to the company's proprietary IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, which utilizes an engineered vaccinia virus strain designed to produce a high proportion of extracellular enveloped virions (EEVs). This modification allows the virus to evade systemic immune clearance and effectively target tumors via intravenous administration. Once inside the tumor, IDOV-2 replicates selectively in cancer cells, causing direct oncolysis and turning the tumor into an anti-tumor 'drug factory' that delivers cytokines, chemokines, or other therapeutic proteins to stimulate local and systemic immune responses. IDOV-2 is currently being evaluated in a first-in-human Phase I clinical trial (NCT06910657) in patients with advanced solid tumors.
Beyond the preview
Go deeper on IDOV-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDOV-2.